Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Sen, Fatma; Tambas, Makbule; Ozkaya, Kubra; Guveli, Murat; Ciftci, Rumeysa; Ozkan, Berker; ORAL, Ethem; KAYTAN SAĞLAM, Esra; Saip, Pinar; Toker, Alper; Demir, Adalet; Firat, Pinar; Aydiner, Adnan; Eralp, YEŞİM

doi:10.1097/md.0000000000004280

Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Atıf İçin Kopyala

Sen F., Tambas M., Ozkaya K., Guveli M. E., Ciftci R., Ozkan B., ...Daha Fazla

MEDICINE, cilt.95, sa.30, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 95 Sayı: 30
Basım Tarihi: 2016
Doi Numarası: 10.1097/md.0000000000004280
Dergi Adı: MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: concomitant chemoradiotherapy, docetaxel-cisplatin, etoposide-cisplatin, locally-advanced NSCLC, lung cancer, VINORELBINE PLUS CISPLATIN, RANDOMIZED PHASE-II, 1ST-LINE TREATMENT, RADIATION-THERAPY, CONCURRENT RADIOTHERAPY, INDUCTION CHEMOTHERAPY, PLATINUM COMBINATIONS, THORACIC RADIATION, STAGE IIIA, TRIAL
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Presently, there is no consensus regarding which chemotherapy regimen is best to administer with radiotherapy in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). Herein, our aim was to compare the outcome of patients treated with either etoposide-cisplatin (EP) or docetaxel-cisplatin (DP) in this curative setting.